Evidence map›Paper›PMID 42436804›Full record

ArticleMaterials today. Bio2026

Orally administered biomimetic nanovesicles engineered with FGF2 orchestrate mucosal healing and microbiome remodeling in inflammatory bowel disease.

Meilin Yi, Jiayi Luo, Ebrahim Abdo, Zuyao Lu, Xin Pan, Xu Han, Xinyi Sun, Yuting Xia, Juqin Dai, Keqing Shi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Meilin YiTranslational Medicine Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Cixi Biomedical Research Institute, Wenzhou Medical University, China.
Jiayi LuoTranslational Medicine Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Cixi Biomedical Research Institute, Wenzhou Medical University, China.
Ebrahim AbdoTranslational Medicine Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Cixi Biomedical Research Institute, Wenzhou Medical University, China.
Zuyao LuTranslational Medicine Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Cixi Biomedical Research Institute, Wenzhou Medical University, China.
Xin PanTranslational Medicine Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Cixi Biomedical Research Institute, Wenzhou Medical University, China.
Xu HanTranslational Medicine Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Cixi Biomedical Research Institute, Wenzhou Medical University, China.
Xinyi SunTranslational Medicine Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Cixi Biomedical Research Institute, Wenzhou Medical University, China.
Yuting XiaTranslational Medicine Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Cixi Biomedical Research Institute, Wenzhou Medical University, China.
Juqin DaiTranslational Medicine Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Cixi Biomedical Research Institute, Wenzhou Medical University, China.
Keqing ShiTranslational Medicine Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Cixi Biomedical Research Institute, Wenzhou Medical University, China.
Zimiao ChenTranslational Medicine Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Cixi Biomedical Research Institute, Wenzhou Medical University, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is characterized by chronic intestinal inflammation and profound microbial dysbiosis, presenting significant therapeutic challenges. While fibroblast growth factor 2 (FGF2) possesses potent regenerative capabilities, its oral administration is severely hindered by rapid gastrointestinal degradation. To overcome these delivery barriers, this study investigates a novel, targeted therapeutic strategy utilizing nanoscale outer membrane vesicles (OMV/FGF2) naturally secreted during the normal growth of FGF2-engineered Gram-negative bacteria. The isolated OMV/FGF2 (120.1 nm, -13.7 mV) maintained robust structural integrity in simulated gastric fluid and demonstrated highly favorable cytocompatibility. In a dextran sulfate sodium (DSS)-induced murine colitis model, orally administered OMV/FGF2 significantly attenuated disease severity, mitigating weight loss and colon shortening. Mechanistically, OMV/FGF2 actively restored the intestinal physicochemical barrier by upregulating tight junction proteins (Occludin, ZO-1) and promoting mucus hypersecretion. Furthermore, 16S rRNA analysis revealed that OMV/FGF2 reversed microbial dysbiosis, enhancing α-diversity and enriching beneficial commensals (e.g.,

Indexed as

Bacterial outer membrane vesiclesFibroblast growth factorInflammatory bowel diseaseIntestinal homeostasisMicrobiota

Identifiers

PMID42436804
PMCPMC13355657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.